1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies

D.A. Pollyea, S. de Botton, A.T. Fathi, E.M. Stein, M.S. Tallman, S. Agresta, C. Bowden, B. Fan, M. Prah, H. Yang, K. Yen, R.M. Stone. University of Colorado Cancer Center, Aurora CO, USA; Institut Gustave Roussy, Villejuif, France; Massachusetts General Hospital Cancer Center, Boston MA, USA; Memorial Sloan-Kettering Cancer Center, New York NY, USA; Agios Pharmaceuticals, Cambridge MA, USA; Dana-Farber Cancer Institute, Boston MA, USA